Abstract
AbstractPyrazinamide plays an important role in tuberculosis treatment; however, its use is complicated by side-effects and challenges with reliable drug susceptibility testing. Resistance to pyrazinamide is largely driven by mutations in pyrazinamidase (pncA), responsible for drug activation, but genetic heterogeneity has hindered development of a molecular diagnostic test. We proposed to use information on how variants were likely to affect the 3D structure of pncA to identify variants likely to lead to pyrazinamide resistance. We curated 610 pncA mutations with high confidence experimental and clinical information on pyrazinamide susceptibility. The molecular consequences of each mutation on protein stability, conformation, and interactions were computationally assessed using our comprehensive suite of graph-based signature methods, mCSM. The molecular consequences of the variants were used to train a classifier with an accuracy of 80%. Our model was tested against internationally curated clinical datasets, achieving up to 85% accuracy. Screening of 600 Victorian clinical isolates identified a set of previously unreported variants, which our model had a 71% agreement with drug susceptibility testing. Here, we have shown the 3D structure of pncA can be used to accurately identify pyrazinamide resistance mutations. SUSPECT-PZA is freely available at: http://biosig.unimelb.edu.au/suspect_pza/.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. WHO. Global Tuberculosis Report, Executive Summary, 2018. https://www.who.int/tb/publications/global_report/tb18_ExecSum_web_4Oct18.pdf?ua=1 (2018).
2. Heifets, L. & Lindholm-Levy, P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. The American review of respiratory disease 145, 1223–1225, https://doi.org/10.1164/ajrccm/145.5.1223 (1992).
3. Tarshis, M. S. & Weed, W. A. Jr. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. American review of tuberculosis 67, 391–395 (1953).
4. Dawson, R. et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (London, England) 385, 1738–1747, https://doi.org/10.1016/s0140-6736(14)62002-x (2015).
5. Veziris, N. et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. American journal of respiratory and critical care medicine 179, 75–79, https://doi.org/10.1164/rccm.200711-1736OC (2009).
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献